---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-009988"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:44:31.012411+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics Raises $100M in Oversubscribed Private Placement Led by BVF Partners

## Summary
- Gross proceeds ~$100M from 1.45M shares, 31.9M pre-funded warrants, and 16.7M warrants at $3.00/share (warrant strike $4.50).
- Private placement led by BVF Partners LP; new investors include Venrock, Vivo Capital, Janus Henderson, Vestal Point, Velan Capital, ADAR1, Stonepine, Sphera Biotech.
- Net proceeds to complete Phase 3 LEVEL trial and initiate second Phase 3 trial of oral levosimendan; cash runway extended through end of 2027.
- Expected to close August 8, 2024; Leerink Partners lead placement agent, with Guggenheim, William Blair as joint agents; ROTH Capital financial advisor.
- Post-closing common shares outstanding expected to be approximately 3.4 million.

## SEC filing metadata
- accession: 0001654954-24-009988
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424009988/0001654954-24-009988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424009988/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-009988
- JSON: https://secwatch.observer/filing/0001654954-24-009988.json
- Plain text: https://secwatch.observer/filing/0001654954-24-009988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.